Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse af JNJ-87189401 Plus JNJ-78278343 til avanceret prostatakræft

2. november 2026 opdateret af: Janssen Research & Development, LLC

En fase 1 undersøgelse af JNJ-87189401 (PSMA-CD28 bispecifikt antistof) kombineret med JNJ-78278343 (KLK2-CD3 bispecifikt antistof) til avanceret prostatakræft

The purpose of Parts 1, 2A, and 2B of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 and the purpose of Part 2C of this study is to determine how safe the RP2R(s) of the combination of JNJ-87189401 and JNJ-78278343 is, with or without apalutamide. Part 3 of this study evaluates the safety of the triplet combination of JNJ-87189401 and JNJ-78278343 with standard of care (SOC) lutetium Lu-177 vipivotide tetraxetan. Part 4 of this study further evaluates the safety of the triplet combination of JNJ-87189401 and JNJ-78278343 with JNJ-101556143 in participants with advanced prostate cancer.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

355

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Greenslopes, Australien, 4120
        • Rekruttering
        • Greenslopes Private Hospital
      • Melbourne, Australien, 3000
        • Rekruttering
        • Peter MacCallum Cancer Centre
    • Colorado
      • Aurora, Colorado, Forenede Stater, 80045
        • Rekruttering
        • University of Colorado Anschutz Medical Campus
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30322
        • Rekruttering
        • Emory University Winship Cancer Institute
    • Minnesota
      • Minneapolis, Minnesota, Forenede Stater, 55455
        • Rekruttering
        • University Of Minnesota
    • New Jersey
      • East Brunswick, New Jersey, Forenede Stater, 08816
        • Rekruttering
        • START New Jersey
    • New York
      • New York, New York, Forenede Stater, 10032
        • Rekruttering
        • Herbert Irving Comprehensive Cancer Center Columbia University Medical Center
      • The Bronx, New York, Forenede Stater, 10467
        • Rekruttering
        • Montefiore Medical Center
    • North Carolina
      • Charlotte, North Carolina, Forenede Stater, 28204
        • Rekruttering
        • Atrium Health Levine Cancer Institute
    • Oregon
      • Portland, Oregon, Forenede Stater, 97239
        • Rekruttering
        • Oregon Health And Science University
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19107
        • Rekruttering
        • Sidney Kimmel Cancer Center - Jefferson Health
    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37203
        • Rekruttering
        • Tennessee Oncology
    • Texas
      • Houston, Texas, Forenede Stater, 77030
        • Rekruttering
        • MD Anderson Cancer Center
      • San Antonio, Texas, Forenede Stater, 78229
        • Rekruttering
        • South Texas Accelerated Research Therapeutics, LLC (START)
    • Washington
      • Seattle, Washington, Forenede Stater, 98104
        • Rekruttering
        • Swedish Medical Center
      • Bordeaux, Frankrig, 33000
        • Rekruttering
        • Institut Bergonie
      • Lyon, Frankrig, 69008
        • Rekruttering
        • Centre Leon Berard
      • Villejuif, Frankrig, 94800
        • Rekruttering
        • Institut Gustave Roussy
      • Tokyo, Japan, 135 8550
        • Rekruttering
        • The Cancer Institute Hospital of JFCR
      • Chongqing, Kina, 400030
        • Rekruttering
        • Chongqing University Cancer Hospital
      • Wenzhou, Kina, 325000
        • Rekruttering
        • The First Affiliated Hospital of Wenzhou Medical University
      • Xi'an, Kina, 710004
        • Rekruttering
        • The First Affiliated Hospital of Xian Jiaotong University

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Han

Beskrivelse

Inclusion Criteria:

  • Histologically confirmed adenocarcinoma of the prostate. Adenocarcinoma with small cell or neuroendocrine (NE) features is permitted. However, small cell carcinoma, carcinoid tumor, mixed NE carcinoma, or large cell NE carcinoma is disallowed
  • Measurable or evaluable disease per PCWG3 criteria
  • Part 1, Parts 2A, 2B, 3 and 4: Prior orchiectomy or medical castration; participants who have not undergone orchiectomy, must be receiving ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH) analog (agonist or antagonist), prior to the first dose of study drug and must continue this therapy throughout the treatment phase
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Exclusion Criteria:

  • History of an autoimmune disease within the 12 months prior to signing consent
  • Any of the following within 6 months prior to signature of informed consent: a. myocardial infarction, b. severe or unstable angina, c. clinically significant ventricular arrhythmias, d. congestive heart failure (New York Heart Association [NYHA] class II to IV), e. transient ischemic attack, and f. Cerebrovascular accident

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Sekventiel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Part 1 (Dose Escalation)

Participants will receive JNJ-78278343 + JNJ-87189401 escalated sequentially in Part 1 to select a recommended Phase 2 regimen (RP2R).

JNJ-87189401 will be administered.

Andre navne:
  • PSMaxCD28

JNJ-78278343 will be administered.

Andre navne:
  • KLK2-CD3
  • Pasritamig
Eksperimentel: Part 2 (Dose Expansion)

Participants with different disease settings in Parts 2A and 2B will receive JNJ-78278343+JNJ-87189401 at the RP2R selected in Part 1. Participants in Part 2C will receive apalutamide plus continued treatment with JNJ-87189401+JNJ-78278343 doublet.

JNJ-87189401 will be administered.

Andre navne:
  • PSMaxCD28

JNJ-78278343 will be administered.

Andre navne:
  • KLK2-CD3
  • Pasritamig

Apalutamide will be administered.

Eksperimentel: Part 3

Participants will receive JNJ-78278343 + JNJ-87189401 at one or more RP2R (s) selected in Part 1 along with standard of care (SOC) treatment with lutetium Lu-177 vipivotide tetraxetan. Dosing of JNJ-78278343+JNJ-87189401 will be escalated sequentially, as per study evaluation team (SET) decision.

JNJ-87189401 will be administered.

Andre navne:
  • PSMaxCD28

JNJ-78278343 will be administered.

Andre navne:
  • KLK2-CD3
  • Pasritamig

Lutetium Lu-177 Vipivotide Tetraxetan will be administered as SOC treatment.

Eksperimentel: Part 4

Participants will receive JNJ-78278343 + JNJ-87189401 at one or more RP2R (s) along with JNJ-101556143. Dosing of JNJ-78278343+JNJ-87189401 along with JNJ-101556143 will be escalated sequentially to determine the RP2R of the combinations.

JNJ-87189401 will be administered.

Andre navne:
  • PSMaxCD28

JNJ-78278343 will be administered.

Andre navne:
  • KLK2-CD3
  • Pasritamig

JNJ-101556143 will be administered.

Andre navne:
  • HLD-0915

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Parts 1, 2C, 3 and 4: Number of Participants With Dose Limiting Toxicity (DLT)
Tidsramme: Up to 21 days after first combination dose of study drugs

DLTs are specific adverse events (AEs) and are defined as any of the following: high grade non-hematologic toxicity or hematologic toxicity.

Up to 21 days after first combination dose of study drugs
Number of Participants with Adverse Events (AEs) by Severity
Tidsramme: Up to 4 years 8 months

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 with the exception of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome events, which will be graded by American Society for Transplantation and Cellular Therapy (ASTCT) guidelines. Severity scale ranges from grade 1 (mild) to grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening and Grade 5= death related to adverse event.

Up to 4 years 8 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Serum Concentrations of JNJ-87189401 and JNJ-78278343
Tidsramme: Up to 4 years 8 months

Serum samples will be analyzed to determine concentrations of JNJ-87189401 and JNJ-78278343.

Up to 4 years 8 months
Plasma Concentration of JNJ-101556143
Tidsramme: Up to 4 years 8 months

Plasma samples will be analyzed to determine concentrations of JNJ-101556143.

Up to 4 years 8 months
Number of Participants With Antibodies to JNJ-87189401 and JNJ-78278343
Tidsramme: Up to 4 years 8 months

Number of participants with antibodies to JNJ-87189401 and JNJ-78278343 will be reported.

Up to 4 years 8 months
Objective Response Rate (ORR)
Tidsramme: Up to 4 years 8 months

ORR is defined as the proportion of participants who have a partial response (PR) or better according to response evaluation criteria in solid tumors (RECIST) version 1.1 without evidence of bone progression according to Prostate Cancer Clinical Trials Working Group 3 (PCWG3).

Up to 4 years 8 months
Radiographic Progression-Free Survival (rPFS)
Tidsramme: Up to 4 years 8 months

rPFS is defined time from the date of first dose of study drug until the date of objective disease progression or death, whichever comes first.

Up to 4 years 8 months
Prostate Specific Antigen (PSA) Response Rate
Tidsramme: Up to 4 years 8 months

PSA response rate is defined as the percentage of participants with a confirmed decline of PSA of 50 percent (%) or more from baseline.

Up to 4 years 8 months
Duration of Response (DOR)
Tidsramme: Up to 4 years 8 months

DOR is defined for participants who achieved response (PR or better) as the time between the date of initial documentation of response (PR or better) to the date of first documented evidence of progressive disease, as defined in the PCWG3, or death due to any cause, whichever occurs first.

Up to 4 years 8 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. november 2023

Primær færdiggørelse (Anslået)

21. juni 2027

Studieafslutning (Anslået)

28. juni 2028

Datoer for studieregistrering

Først indsendt

18. oktober 2023

Først indsendt, der opfyldte QC-kriterier

18. oktober 2023

Først opslået (Faktiske)

23. oktober 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

3. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • CR109330
  • 87189401PCR1001 (Anden identifikator: Janssen Research & Development, LLC)
  • 2023-504063-17-00 (Registry Identifier: EUCT number)
  • 2023 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .